COMMITTEE MEMBERS

Wallace J. Hopp, Ph.D. (Chair), studies the design, control, and management of operations systems, with emphasis on manufacturing and supply chain systems, innovation processes, and health care systems. His teaching and research in these areas has been recognized with a number of awards, including being named a Fellow of Institute of International Education, Institute for Operations Research and the Management Sciences, SME, Manufacturing & Service Operations Management, and the Production and Operations Management Society (POMS), and his election to the National Academy of Engineering. He has previously served as President of POMS, as Editor-in-Chief of the journal Management Science, and is currently a founding editor of the Management and Business Review. He is an active industry consultant whose clients have included many Fortune 500 firms.

Mahshid Abir, M.D., M.Sc., is an associate professor in emergency medicine at the University of Michigan (U-M) and a Senior Physician Policy Researcher at the RAND Corporation. She is the director of the Acute Care Research Unit at the U-M Institute for Healthcare Policy and Innovation. Her health services and policy research is focused on improving acute care delivery along the continuum of care during routine and catastrophic conditions, including in the ambulatory care, prehospital, emergency department, and inpatient settings. She has been an integral member of several teams of researchers at RAND, developing various aspects of the National Health Security Strategy funded by the Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response; developing tools to measure hospital and health care coalition surge capacity in response to mass casualty incidents, including a tool designed to evaluate community disaster preparedness. More recently, Dr. Abir has led an internally funded RAND project evaluating strategies for critical care surge capacity in the United States in response to the COVID-19 pandemic, as well as a project funded by the Assistant Secretary for Planning and Evaluation comparing national and international approaches to pandemic-related outcome measurement.

George Ball, Ph.D., M.B.A., is an associate professor of operations and decision technologies and the Weimer Faculty Fellow at the Kelley School of Business, Indiana University, Bloomington. George’s research focuses on medical devices and pharmaceutical supply chain quality, and in particular, medical product recalls. George has conducted several collaborative research projects with the Center for Device and Radiological Health and the Center for Drug Evaluation and Research at the Food and Drug Administration (FDA). In particular, George was a co-principal investigator for a large multiuniversity, multimillion-dollar federal contract with FDA to identify unique predictors of drug shortage and drug quality risks. George’s research has been published in several top-tier journals including Management Science, Manufacturing & Service Operations Management, and the Journal of Operations Management. Prior to his time at Indiana University, George spent 11 years in various manager and director roles at two major medical device companies and 5 years on active duty as a U.S. Naval Officer. George received his Ph.D. in supply chain and operations, an M.B.A. from the Carlson School of Management at the University of Minnesota, and a B.S. in aerospace engineering from the U.S. Naval Academy.

Lee Branstetter, Ph.D., is a professor of economics and public policy at Carnegie Mellon University with a joint appointment to the Social and Decision Sciences Department. He joined the Heinz College faculty in 2006 as a tenured associate professor. Dr. Branstetter is also a research associate of the National Bureau of Economic Research and nonresident senior fellow at the Peterson Institute for International Economics. From 2011 to 2012, he served as the Senior Economist for International Trade and Investment for the President’s Council of Economic Advisors. Prior to coming to Carnegie Mellon, he was the Daniel J. Stanton Associate Professor of Business and the Director of the International Business Program at Columbia Business School. Dr. Branstetter has also taught at the University of California, Davis, where he was the director of the East Asian Studies Program, and at Dartmouth College. He has served as a consultant to the Organisation for Economic Co-operation and Development Science and Technology Directorate, the Advanced Technology Program of the U.S. Department of Commerce, and the World Bank. In recent years, Dr. Branstetter has been a research fellow of the Keio University Global Security Research Institute and a visiting fellow of the Research Institute of Economy, Trade, and Industry in Japan. Branstetter holds a B.A. in economics and mathematical methods in the social sciences from Northwestern University, and he earned his Ph.D. in economics at Harvard in 1996.

Robert Califf, M.D., MACC, is the Head of Clinical Policy and Strategy for Verily and Google Health. Previously, Dr. Califf was the vice chancellor for health data science for the Duke University School of Medicine, director of Duke Forge, Duke’s Center for Health Data Science, and the Donald F. Fortin, M.D., Professor of Cardiology. He served as Deputy Commissioner for Medical Products and Tobacco in the U.S. Food and Drug Administration (FDA) from 2015 to 2016, and as Commissioner of Food and Drugs from 2016 to 2017. Prior to joining FDA, Dr. Califf was a professor of medicine and vice chancellor for clinical and translational research at Duke University. He was the founding director of the Duke Clinical Research Institute. As a nationally and internationally recognized expert in cardiovascular medicine, health outcomes research, health care quality, and clinical research, Dr. Califf has led many landmark clinical trials and is one of the most frequently cited authors in biomedical science, with 1,250 publications in peer-reviewed literature. Dr. Califf is also a member of the National Academy of Medicine (formerly the Institute of Medicine [IOM]). Dr. Califf has served on numerous IOM committees, and was a member of the FDA Cardiorenal Advisory Panel and FDA Science Board’s Subcommittee on Science and Technology. Dr. Califf has also served on the Board of Scientific Counselors for the National Library of Medicine, as well as on advisory committees for the National Cancer Institute, the National Heart, Lung, and Blood Institute, the National Institute of Environmental Health Sciences, and the Council of the National Institute on Aging. He has led major initiatives aimed at improving methods and infrastructure for clinical research, including the Clinical Trials Transformation Initiative, a public–private partnership co-founded by FDA and Duke. He also has served as the principal investigator for Duke’s Clinical and Translational Science Award, the National Institutes of Health Health Care Systems Research Collaboratory coordinating center, and as co-PI of the National Patient-Centered Clinical Research Network (PCORnet). He currently serves as chair of the board of the People-Centered Research Foundation, a not-for-profit organization that is supporting and extending the work of PCORnet.

Asha Devereaux, M.D., M.P.H., completed her medical degree in biology from the University of California, San Diego, followed by a M.D. and M.P.H. from Tulane University School of Medicine and Public Health. Upon graduation, she served in the United States Navy achieving the rank of Commander while receiving board certification in internal medicine, pulmonology, and critical care. During her 11-year naval career, Dr. Devereaux served on the Navy Surgeon General’s Panel for Tobacco Cessation, served as Head of Medicine at Beaufort Naval Hospital, served on numerous committees, and spent three years covering the USNS Mercy’s Chem/Bio intensive care unit. She is currently on staff at Sharp-Coronado Hospital. In addition to her private practice of pulmonary medicine, she has co-chaired and remains on the Executive Committee of the American College of Chest Physicians (ACCP) Mass Critical Care Task Force, has served on National Academy of Medicine and Centers for Disease Control and Prevention panels for influenza, anthrax, and crisis care, is Past-Chairman of the ACCP Disaster Response Network, and is a former President of the California Thoracic Society. She has responded to natural disasters ranging from fires to hurricanes with the Medical Reserve Corps, the National Disaster Medical System, and as the Senior Medical Officer for San Diego CAL-MAT. She has provided care in Alternate Care Sites for COVID-19 throughout Southern California. Dr. Devereaux was selected as a Top Doctor in San Diego in 2009 and 2021 and was named the Outstanding Pulmonologist by the California Thoracic Society in 2017 by her peers.

Özlem Ergun, Ph.D., is a professor and associate chair for graduate affairs in mechanical and industrial engineering at Northeastern University. Dr. Ergun’s research focuses on design and management of large-scale and decentralized networks. She has applied her work on network design, management, and resilience to problems arising in many critical systems including transportation, pharmaceuticals, and health care. She has worked with organizations that respond to emergencies and humanitarian crises around the world. She was the President of INFORMS Section on Public Programs, Service and Needs in 2013. She currently serves as the Area Editor at the Operations Research journal for policy modeling and the public sector area, and a Department Editor for the journal of Manufacturing & Service Operations Management within the Environment, Health and Society Department. Dr. Ergun is also a founding co-chair of the annual Health and Humanitarian Logistics Conference, held annually since 2009. In addition, Dr. Ergun was the Vice President of Membership and Professional Recognition on the INFORMS Board of Directors from 2011 to 2015. Prior to joining Northeastern, Dr. Ergun was the Coca-Cola Associate Professor in the School of Industrial and Systems Engineering at Georgia Institute of Technology, where she also co-founded and co-directed the Health and Humanitarian Systems Research Center at the Supply Chain and Logistics Institute. She received a B.S. in operations research and industrial engineering from Cornell University in 1996 and a Ph.D. in operations research from the Massachusetts Institute of Technology in 2001.

Erin Fox, Pharm.D, BCPS, FASHP, is senior pharmacy director of the Department of Pharmacy Services at University of Utah Health. Erin is also associate professor (adjunct), at the Department of Pharmacotherapy, University of Utah College of Pharmacy. The University of Utah Drug Information Service provides content for the American Society of Health-System Pharmacists (ASHP) Drug Shortage Resource Center and Erin serves as a media resource and advocate for changes to improve the ongoing drug shortage situation and rising drug costs. Erin is also active in both state and national pharmacy and health-related societies serving in a variety of volunteer and elected positions. Erin is recognized as an expert in drug shortages and has received the ISMP Cheers Award and ASHP Award of Excellence in recognition for her work on drug shortages. Erin has also been honored with the William A. Zellmer Lecture award for her advocacy efforts to address drug shortages and rising drug prices.

Larry M. Glasscock, B.A., is a businessperson who has been either at the helm of, or has provided executive leadership for, companies across a variety of segments. Presently, Mr. Glasscock holds the position of Chief Operating Officer of NFH, Inc. and serves in an executive advisory capacity for MNX Global Logistics. Mr. Glasscock serves on the Board of Kershaw’s Challenge, a public charity founded by Ellen and Clayton Kershaw, and is a member of the Radiopharmaceutical Shippers and Carriers Conference. Mr. Glasscock has extensive experience in the development of unique, global supply chain solutions for health care and medical research companies of all types with specific leadership in nuclear medicine and immunotherapy. He is known to be particularly adept at forming partnerships and alliances for the benefit of manufacturers, researchers, treatment centers, and patients throughout the world.

Lewis Grossman, J.D., Ph.D., is professor of law at the Washington College of Law, where he has taught since 1997 and where he served as Associate Dean for Scholarship from 2008 to 2011. He teaches and writes in the areas of food and drug law, health law, American legal history, and civil procedure. He has also been a visiting professor of law at Cornell Law School and a Law and Public Affairs (LAPA) Fellow at Princeton University. Prior to joining the American University faculty, he was an associate at Covington & Burling LLP in Washington, D.C. Previously, he clerked for Chief Judge Abner Mikva of the U.S. Court of Appeals for the D.C. Circuit. Professor Grossman’s scholarship has appeared in the Cornell Law Review, Law and History Review, Yale Journal of Health Policy, Law& Ethics, and Administrative Law Review, among others. He has made recent contributions to volumes published by Oxford University Press and Columbia University Press. He is the co-author of Food and Drug Law: Cases and Materials (with Peter Barton Hutt and Richard A. Merrill), and of a widely used supplement to the first-year civil procedure course titled A Documentary Companion to A Civil Action (with Robert G. Vaughn). In 2021, Oxford University Press published Professor Grossman’s book titled Choose Your Medicine: Freedom of Therapeutic Choice in America. He has served as a member or legal consultant on three previous committees of the Health and Medicine Division of the National Academies of Sciences, Engineering, and Medicine (formerly the Institute of Medicine). Professor Grossman earned his Ph.D. in history from Yale University, where he was awarded the George Washington Egleston Prize for Best Dissertation in the Field of American History. He received a J.D. magna cum laude from Harvard Law School and a B.A. summa cum laude from Yale University.

W. Craig Vanderwagen, M.D., RADM, USPHS, is a family physician who retired as a Rear Admiral in the United States Public Health Service in 2009. He served for 25 years in the Indian Health Service, the federal program of medical and public health services for American Indians and Alaska Natives. During this time, he also served as the lead health official at a number of disasters including medical care for Kosovar refugees (1999); advisor to the Afghan Ministry of Health (2002); director of public health and advisor to the Iraq Ministry of Health (2003-2004); the USNS Mercy’s response to the 2004 tsunami; and commander of the public health and medical response to Hurricanes Katrina/Rita. Dr. Vanderwagen’s last federal assignment (2006-2009) was as the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (HHS). He was responsible for leading all federal public health and medical assets in disaster response, as well as for guiding the $11 billion HHS medical countermeasure advanced development program to address chemical, biological, radiological and nuclear threats which now has over 100 products in the development pipeline. Dr. Vanderwagen is a Director and General Manager of East West Protection, a Potomac, Maryland, based firm he co-founded with Fuad El Hibri, specializing in public health and medical preparedness, detection, response, and command and control systems for CBRN threats and other disasters. He also has equity in a company that builds specialized vehicles (E-N-G Mobile Systems) and a company that builds long-endurance drones for commercial and other uses (ARS). He is Immediate Past Chairman of the Board at VIDO-Intervac, a Canadian vaccine research and development company. He is also a senior partner at Martin, Blanck, and Associates, a consulting firm of retired generals and flag officers specializing in military health matters. He is a frequent public speaker on biodefense, public health preparedness, and leadership.

Alastair Wood, M.D., was professor of both medicine and pharmacology at Vanderbilt University Medical School and served as both Assistant Vice Chancellor for Clinical Research and Associate Dean at Vanderbilt Medical School, before being appointed Emeritus Professor of Medicine and Emeritus Professor of Pharmacology in 2006. He served as the Drug Therapy Section Editor of the New England Journal of Medicine from 1985 to 2004. He was a Partner at Symphony Capital LLC, a private equity company investing in the clinical development of novel biopharmaceutical products from 2006 to 2018. Dr. Wood has been honored by being elected to the National Academy of Medicine (formerly the Institute of Medicine), the American Association of Physicians, the American Society for Clinical Investigation, Honorary Fellow in the American Gynecological and Obstetrical Society, Fellowship of the American College of Physicians, Fellowship of the Royal College of Physicians of London, and Fellowship of the Royal College of Physicians of Edinburgh. He was the 2005 recipient of the Rawls-Palmer Award and in 2008 received the honorary degree of Doctor of Laws, honoris causa, from the University of Dundee. Dr. Wood has served on a number of editorial boards including the New England Journal of Medicine editorial board and his research has resulted in over 300 articles, reviews, and editorials.

Matthew K. Wynia, M.D., M.P.H., has had a career that includes developing a research institute and training programs focusing on bioethics, professionalism and policy issues (the American Medical Association [AMA] Institute for Ethics), and founding the AMA’s Center for Patient Safety. His research has focused on novel uses of survey data to inform and improve the practical management of ethical issues in health care and public policy. He has led projects on a wide variety of topics related to ethics and professionalism, including understanding and measuring the ethical climate of health care organizations and systems; ethics and quality improvement; communication, team-based care, and engaging patients as members of a team; defining physician professionalism; public health and disaster ethics; medicine and the Holocaust, with the United States Holocaust Memorial Museum; and inequities in health and health care. He has served on committees, expert panels, and as a reviewer for the National Academies, The Joint Commission, the Hastings Center, the American Board of Medical Specialties, federal agencies, and other organizations. Dr. Wynia is the author of more than 160 published articles, chapters, and essays, co-editor of several books, and co-author of a book on fairness in health care benefit design. His work has been published in JAMA, the New England Journal of Medicine, Annals of Internal Medicine, Health Affairs, and other leading medical and ethics journals, and he is a contributing editor for the American Journal of Bioethics. He has discussed his work as a guest on the BBC, ABC News, and National Public Radio, among others. Dr. Wynia is a past president of the American Society for Bioethics and Humanities, and has chaired both the Ethics Forum of the American Public Health Association and the Ethics Committee of the Society for General Internal Medicine.

STAFF

Lisa Brown, M.P.H. (Study Codirector), is a Senior Program Officer on the Board on Health Sciences Policy at the National Academies of Sciences, Engineering, and Medicine (the National Academies) and develops and manages projects at the National Academies related to solving the nation’s most pressing health security issues. She currently serves as a director for the Standing Committee on Emerging Infectious Diseases and 21st Century Health Threats and the Security of America’s Medical Product Supply Chain. She has directed several projects, including the Committee on Equitable Allocation of Vaccine for the Novel Coronavirus, the Committee on Data Needs to Monitor Evolution of SARS-CoV-2, the Committee on Evidence-Based Practices for Public Health Emergency Preparedness and Response, and the Committee on Strengthening the Disaster Resilience of Academic Research Communities. Prior to the National Academies, Lisa served as Senior Program Analyst for Public Health Preparedness and Environment Health at the National Association of County and City Health Officials (NACCHO). In this capacity, Lisa served as project lead for medical countermeasures and the Strategic National Stockpile, researched radiation preparedness issues, and was involved in high-level Centers for Disease Control and Prevention (CDC) initiatives for the development of clinical guidance for anthrax and botulism countermeasures in a mass casualty event. In 2015, Lisa was selected as a fellow in the Emerging Leaders in Biosecurity Initiative at the Center for Health Security, a highly competitive program to prepare the next generation of leaders in the field of biosecurity. Prior to her work at NACCHO, Lisa worked as an Environmental Public Health Scientist at Public Health England (PHE) in London, England. While at PHE, she focused on climate change, the recovery process following disasters, and the impact of droughts and floods on emerging infectious diseases. Lisa received her master of public health from King’s College London in 2012 and her bachelor of science in biology from The University of Findlay in 2010.

Carolyn Shore, Ph.D. (Study Codirector), is director of the Forum on Drug Discovery, Development, and Translation and a senior program officer with the Board on Health Sciences Policy of the National Academies of Sciences, Engineering, and Medicine. Before joining the National Academies, Carolyn was an officer on Pew’s antibiotic resistance project, leading work on research and policies to spur the discovery and development of urgently needed antibacterial therapies. She previously served as a foreign affairs officer at the U.S. Department of State, where she led an initiative on open data and innovation-based solutions to global challenges. She also served as the State Department’s representative to intergovernmental organizations focusing on food safety, plant and animal health, biosecurity, and agricultural trade policy. Carolyn was an American Society for Microbiology congressional fellow, working on science-based policy related to antibiotic stewardship and other public health issues. She holds a doctoral degree in microbiology and molecular genetics from Harvard University. As a graduate student, she studied anti-malarial drug resistance in Senegal and worked jointly between the Medicines for Malaria Venture, Genzyme Corporation, and the Broad Institute of Harvard and MIT to discover new anti-malarial compounds. Carolyn was awarded a Fulbright Fellowship for work at the University of Queensland in Brisbane, Australia, and a National Institutes of Health Training Grant for postdoctoral work at the University of Iowa.

Kelsey R. Babik, M.P.H., is an Associate Program Officer in the Health Medicine Division at the National Academies of Sciences, Engineering, and Medicine. In addition to this study, she works on projects initiated by the Committee on Personal Protective Equipment for Workplace Safety and Health. This is a standing committee at the National Academies of Sciences, Engineering, and Medicine sponsored by the National Personal Protective Technology Laboratory of the National Institute for Occupational Safety and Health, to provide a forum for discussion of scientific and technical issues relevant to the development, certification, deployment, and use of personal protective equipment, standards, and related systems to ensure workplace safety and health. Previously, at the Risk Sciences and Public Policy Institute of the Johns Hopkins Bloomberg School of Public Health, she worked on occupational health risk assessments for first responders. She has a B.S. in molecular biology from the University of Pittsburgh and an M.P.H. from the University of Maryland.

Leah Cairns, Ph.D., is a Program Officer on the Board on Health Sciences Policy. Her primary interests include health policy and biomedical research. Prior to joining the National Academies, she served as a Science and Technology Policy Fellow for the Association for the Advancement of Science working as legislative staff for a member of Congress focusing on health policy and appropriations. Dr. Cairns also previously served as a Christine Mirzayan Science & Technology Policy Fellow at the National Academies in the Policy and Global Affairs Division. Dr. Cairns received her Ph.D. in biophysics from the Johns Hopkins University School of Medicine and a B.A. in biochemistry and molecular biology from Hamilton College.

Melvin Joppy, B.S., is a Senior Program Assistant on the Board on Health Sciences Policy, with the Forum on Drug Discovery, Development, and Translation. He was recently a Program Assistant at the Department of Energy (DOE) working in the Office of Basic Energy Sciences. Prior to DOE, Melvin served as the Committee Manager for the Presidential Advisory Council on HIV/AIDS within the U.S. Department of Health and Human Services. Melvin received his B.S. in communications from Bowie State University.

Andrew March, M.P.H., is an Associate Program Officer on the Board on Health Sciences Policy, with the Forum on Drug Discovery, Development, and Translation. Andrew joined the National Academies in 2018. His previous work at the Academies includes consensus studies on dementia care interventions, and the safety and effectiveness of compounded drug preparations. Prior to coming to the National Academies, he performed research on sickness absence in working women at the Center for Research in Occupational Health, and worked in the Epidemiology Department at the Hospital de la Santa Creu i Sant Pau. Andrew obtained his M.P.H. at the Universitat Pompeu Fabra and his B.S. degree in biology and Spanish from Roanoke College.

Margaret McCarthy, M.Sc., is a Research Associate with the Board on Health Sciences Policy. She is currently working with the Committee on the Security of America’s Medical Product Supply Chain and the Standing Committee for CDC Preparedness and Response. In 2018, Margaret interned with Committee on Human Rights and Office of News and Public Information, where she collaborated with fellow colleagues to organize the Second International Summit on Human Genome Editing. Before rejoining the National Academies as a Research Associate, she previously worked at Brigham and Women’s Hospital in Boston, Massachusetts, as an infectious diseases research assistant. Her interests include migration, biosecurity, and European politics. Margaret received her B.A. in international studies from American University and her M.Sc. in global health and development from University College, London.

Shalini Singaravelu, M.Sc., is an Associate Program Officer on the Board on Health Sciences Policy and works on the Standing Committee on Emerging Infectious Diseases and 21st Century Health Threats. Prior to joining the National Academies, Shalini managed a portfolio of digital health tools as a Program Manager at IBM. From 2015 to 2019, she was a consultant for the World Health Organization Health Emergencies Programme in Geneva. In this role, she supported preparedness and response to emerging infectious disease epidemics with a focus on operational data systems, risk communication, and community engagement. Before this, she worked on psychosocial support programming for HIV-affected orphans and vulnerable children in South Africa. Shalini has a graduate certificate in risk sciences and public policy from Johns Hopkins Bloomberg School of Public Health (2021), where she is currently a part-time doctor of public health (Dr.P.H.) student in health security. She received her M.Sc. in global mental health from London School of Hygiene and Tropical Medicine (2014) and her B.A. in anthropology from Union College (2012).